Clinical Report: Evaluating the Prognostic Value of Inflammation-Related Markers in Nasopharyngeal Carcinoma
Overview
This systematic review and meta-analysis evaluated the prognostic value of inflammation-based indices in nasopharyngeal carcinoma (NPC). The pooled hazard ratio (HR) for overall survival (OS) was 1.86 (95% CI: 1.42–2.43) and for progression-free survival (PFS) was 1.74 (95% CI: 1.31–2.30).
Background
Nasopharyngeal carcinoma (NPC) is a malignancy with unique epidemiological and biological characteristics, particularly prevalent in Southeast Asia and linked to Epstein-Barr virus infection. Recurrence and metastasis remain significant challenges. Understanding prognostic factors, including systemic inflammation markers, is crucial for improving patient management.
Data Highlights
Marker
Pooled HR for OS
Pooled HR for PFS
SII
2.01
-
SIRI
1.93
-
LMR
0.72
-
Key Findings
Pooled HR for overall survival (OS) was 1.86 (95% CI: 1.42–2.43).
Pooled HR for progression-free survival (PFS) was 1.74 (95% CI: 1.31–2.30).
SII and SIRI had the strongest associations with poor outcomes (HR = 2.01 and 1.93, respectively).
A higher LMR was associated with better prognosis (HR = 0.72, 95% CI: 0.53–0.98).
No significant publication bias was detected.
Clinical Implications
The findings suggest that systemic inflammation-based biomarkers, particularly SII and SIRI, could serve as independent predictors of survival in NPC. Their integration into clinical practice may enhance prognostic stratification.
Conclusion
Systemic inflammation-based biomarkers are significant predictors of survival in NPC.
